Emerging drugs for the treatment of clostridium difficile

References

• Lawson PA, Citron DM, Tyrrell KL, et al. Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O’Toole 1935) Prévot 1938. Anaerobe. 2016;40:95–99.
   PubMed Web of Science ®Google Scholar
• Kelly CP, LaMont JT. Clostridium difficile – more difficult than ever. N Engl J Med. 2008;359:1932–1940.
   PubMed Web of Science ®Google Scholar
• Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015;372:1539–1548.
   PubMed Web of Science ®Google Scholar
• Abou Chakra CN, Pépin J, Sirard S, et al. Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PLoS One. 2014;9:e98400.
   PubMed Web of Science ®Google Scholar
• Freeman J, Bauer MP, Baines SD, et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev. 2010;23:529–549.
   PubMed Web of Science ®Google Scholar
• Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372:825–834.
   PubMed Web of Science ®Google Scholar
• Ma GK, Brensinger CM, Wu Q, et al. Increasing incidence of multiply recurrent Clostridium difficile infection in the United States: a cohort study. Ann Intern Med. 2017;167:152–158.
   PubMed Web of Science ®Google Scholar
• Leibovici-Weissman Y, Atamna A, Schlesinger A, et al. Risk factors for short- and long-term mortality in very old patients with Clostridium difficile infection: a retrospective study. Geriatr Gerontol Int. 2017;17:1378–1383.
   PubMed Web of Science ®Google Scholar
• Shields K, Araujo-Castillo RV, Theethira TG, et al. Recurrent Clostridium difficile infection: from colonization to cure. Anaerobe. 2015;34:59–73.
   PubMed Web of Science ®Google Scholar
• Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis. 2012;55(Suppl 2):S88–S92.
   PubMed Web of Science ®Google Scholar
• Zhang S, Palazuelos-Munoz S, Balsells EM, et al. Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study. BMC Infect Dis. 2016;16:447.
   PubMed Web of Science ®Google Scholar
• McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66:987–994.
   PubMed Web of Science ®Google Scholar
• Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108:478–498.
   PubMed Web of Science ®Google Scholar
• Du Pont HL. The search for effective treatment of Clostridium difficile infection. N Engl J Med. 2011;364:473–475.
   PubMed Web of Science ®Google Scholar
• Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45:302–307.
   PubMed Web of Science ®Google Scholar
• Al-Nassir WN, Sethi AK, Li Y, et al. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother. 2008;52:2403–2406.
   PubMed Web of Science ®Google Scholar
• Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin Infect Dis. 2008;46(Suppl 1):S32–S42.
   PubMedGoogle Scholar
• Reynolds PE. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis. 1989;8:943–950.
   PubMed Web of Science ®Google Scholar
• Fernandez A, Anand G, Friedenberg F. Factors associated with failure of metronidazole in Clostridium difficile-associated disease. J Clin Gastroenterol. 2004;38:414–418.
   PubMed Web of Science ®Google Scholar
• Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis. 2005;5:549–557.
   PubMed Web of Science ®Google Scholar
• Johnson S, Louie TJ, Gerding DN, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis. 2014;59:345–354.
   PubMed Web of Science ®Google Scholar
• Peng Z, Jin D, Kim HB, et al. Update on antimicrobial resistance in Clostridium difficile: resistance mechanisms and antimicrobial susceptibility testing. J Clin Microbiol. 2017;55:1998–2008.
   PubMed Web of Science ®Google Scholar
• Sarna JR, Furtado S, Brownell AKW. Neurologic complications of metronidazole. Can J Neurol Sci. 2013;40:768–776.
   PubMed Web of Science ®Google Scholar
• Chai J, Lee CH. Management of primary and recurrent Clostridium difficile infection: an update. antibiotics (Basel). 2018;7(3):54.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Walkty AJ, Karlowsky JA. Fidaxomicin: a novel agent for the treatment of Clostridium difficile infection. Can J Infect Dis Med Microbiol. 2015;26:305–312.
   PubMed Web of Science ®Google Scholar
• Babakhani F, Bouillaut L, Gomez A, et al. Fidaxomicin inhibits spore production in Clostridium difficile. Clin Infect Dis. 2012;55:S162–S169.
   PubMed Web of Science ®Google Scholar
• Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364:422–431.
   PubMed Web of Science ®Google Scholar
• Crook DW, Walker AS, Kean Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis. 2012;55:S93–S103.
   PubMed Web of Science ®Google Scholar
• Scott LJ. Fidaxomicin: a review of its use in patients with Clostridium difficile infection. Drugs. 2013;73:1733–1747.
   PubMed Web of Science ®Google Scholar
• Gerding DN, File TM, McDonald LC. Diagnosis and treatment of Clostridium difficile infection (CDI). Infect Dis Clin Pract (Baltim Md). 2016;24(1):3–10.
   PubMed Web of Science ®Google Scholar
• Peng Z, Ling L, Stratton CW, et al. Advances in the diagnosis and treatment of Clostridium difficile infections. Emerg Microbes Infect. 2018;7(1):1–13.
   Google Scholar
• Spigaglia P, Mastrantonio P, Barbanti F. Antibiotic resistances of Clostridium difficile. Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions. Adv Exp Med Biol. 2018;1050:137–159.
   PubMedGoogle Scholar
• Ghantoji SS, Sail K, Lairson DR, et al. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect. 2010;74:309–318.
   PubMed Web of Science ®Google Scholar
• Heimann SM, Cruz Aguilar MR, Mellinghof S, et al. Economic burden and cost-effective management of Clostridium difficile infections. Med Mal Infect. 2018;48:23–29.
   PubMed Web of Science ®Google Scholar
• Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database Syst Rev. 2017;3:CD004610.
   PubMed Web of Science ®Google Scholar
• Wagner M, Lavoie L, Goetghebeur M. Clinical and economic consequences of vancomycin and fidaxomicin for the treatment of Clostridium difficile infection in Canada. Can J Infect Dis Med Microbiol. 2014;25:87–94.
   PubMed Web of Science ®Google Scholar
• Burton HE, Mitchell SA, Watt M. A systematic literature review of economic evaluations of antibiotic treatments for Clostridium difficile infection. Pharmacoeconomics. 2017;35:1123–1140.
   PubMed Web of Science ®Google Scholar
• Baktash A, Terveer EM, Zwittink RD, et al. Mechanistic insights in the success of fecal microbiota transplants for the treatment of Clostridium difficile infections. Front Microbiol. 2018;9:1242.
   PubMed Web of Science ®Google Scholar
• Sommer F, Bäckhed F. The gut microbiota–masters of host development and physiology. Nat Rev Microbiol. 2013;11:227–238.
   PubMed Web of Science ®Google Scholar
• Callaway TR, Edrington TS, Anderson RC, et al. Probiotics, prebiotics and competitive exclusion for prophylaxis against bacterial disease. Anim Health Res Rev. 2008;9:217–225.
   PubMedGoogle Scholar
• Kamada N, Chen G, Núñez G. A complex microworld in the gut: harnessing pathogen-commensal relations. Nat Med. 2012;18:1190–1191.
   PubMed Web of Science ®Google Scholar
• Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005;308:1635–1638.
   PubMed Web of Science ®Google Scholar
• Proctor LM. The human microbiome project in 2011 and beyond. Cell Host Microbe. 2011;10:287–291.
   PubMed Web of Science ®Google Scholar
• Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature. 2011;473:174–180.
   PubMed Web of Science ®Google Scholar
• Britton RA, Young VB. Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends Microbiol. 2012;20:313–319.
   PubMed Web of Science ®Google Scholar
• Robinson CJ, Young VB. Antibiotic administration alters the community structure of the gastrointestinal micobiota. Gut Microbes. 2010;1:279–284.
   PubMed Web of Science ®Google Scholar
• Dethlefsen L, Huse S, Sogin ML, et al. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 2008;6:e280.
   PubMed Web of Science ®Google Scholar
• Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis. 2008;197:435–438.
   PubMed Web of Science ®Google Scholar
• Seekatz AM, Rao K, Santhosh K, et al. Dynamics of the fecal microbiome in patients with recurrent and nonrecurrent Clostridium difficile infection. Genome Med. 2016;8:47.
   PubMed Web of Science ®Google Scholar
• Khoruts A, Dicksved J, Jansson JK, et al. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol. 2010;44:354–360.
   PubMed Web of Science ®Google Scholar
• Britton RA, Young VB. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology. 2014;146:1547–1553.
   PubMed Web of Science ®Google Scholar
• Gerding DN, Johnson S. Management of Clostridium difficile infection: thinking inside and outside the box. Clin Infect Dis. 2010;51:1306–1313.
   PubMed Web of Science ®Google Scholar
• Allen CA, Babakhani F, Sears P, et al. Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores. Antimicrob Agents Chemother. 2013;57:664–667.
   PubMed Web of Science ®Google Scholar
• Petrosillo N, Granata G, Cataldo MA. Novel antimicrobials for the treatment of Clostridium difficile infection. Front Med (Lausanne). 2018;5:96.
   PubMed Web of Science ®Google Scholar
• Roshan N, Hammer KA, Riley TV. Non-conventional antimicrobial and alternative therapies for the treatment of Clostridium difficile infection. Anaerobe. 2018;49:103–111.
   PubMed Web of Science ®Google Scholar
• Daley P, Louie T, Lutz JE, et al. Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial. J Antimicrob Chemother. 2017;72:3462–3470.
   PubMed Web of Science ®Google Scholar
• Boix V, Fedorak RN, Mullane KM, et al. Primary outcomes from a Phase 3, randomized, double-blind, active-controlled trial of surotomycin in subjects with Clostridium difficile infection. Open Forum Infect Dis. 2017;4:ofw275.
   PubMed Web of Science ®Google Scholar
• Louie T, Nord CE, Talbot GH, et al. Multicenter, double-blind, randomized, Phase 2 study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection. Antimicrob Agents Chemother. 2015;59:6266–6273.
   PubMed Web of Science ®Google Scholar
• Wullt M, Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J Antimicrob Chemother. 2004;54:211–216.
   PubMed Web of Science ®Google Scholar
• Norén T, Wullt M, Akerlund T, et al. Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid. Antimicrob Agents Chemother. 2006;50:3018–3032.
   Web of Science ®Google Scholar
• Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis. 2006;43:421–427.
   PubMed Web of Science ®Google Scholar
• Musher DM, Logan N, Bressler AM, et al. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis. 2009;48(4):e41–e46.
   PubMed Web of Science ®Google Scholar
• Vickers RJ, Tillotson GS, Nathan R, et al. Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study. Lancet Infect Dis. 2017;17:735–744.
   PubMed Web of Science ®Google Scholar
• Mullane K, Lee C, Bressler A, et al. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. Antimicrob Agents Chemother. 2015;59(3):1435–1440.
   PubMed Web of Science ®Google Scholar
• Fulco P, Wenzel RP. Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent. Expert Rev Anti Infect Ther. 2006;4:939–945.
   PubMedGoogle Scholar
• Navalkele BD, Chopra T. Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection. Biologics. 2018;12:11–21.
   PubMed Web of Science ®Google Scholar
• Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017;376:305–317.
   PubMed Web of Science ®Google Scholar
• Clostridium difficile vaccine efficacy trial (Clover). cited 2018 Apr 22. Available from: https://clinicaltrials.gov/ct2/show/NCT03090191
   Google Scholar
• Sanofi ends development of Clostridium difficile vaccine (Press Release). 2017 Dec 1 cited 2018 Apr 22. Available from: http://mediaroom.sanofi.com/sanofi-ends-development-of-clostridium-difficile-vaccine/
   Google Scholar
• Henderson M, Bragg A, Fahim G, et al. A review of the safety and efficacy of vaccines as prophylaxis for Clostridium difficile infections. Vaccines (Basel). 2017;5(3):25.
   PubMed Web of Science ®Google Scholar
• Khanna S, Pardi DS, Kelly CR, et al. A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J Infect Dis. 2016;214:173–181.
   PubMed Web of Science ®Google Scholar
• Gerding DN, Meyer T, Lee C, et al. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA. 2015;313:1719–1727.
   PubMed Web of Science ®Google Scholar
• van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407–415.
   PubMed Web of Science ®Google Scholar
• Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;41:835–843.
   PubMed Web of Science ®Google Scholar
• Quraishi MN, Widlak M, Bhala N, et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther. 2017;46:479–493.
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Yuan Y, Baharith H, et al. Faecal microbiota transplantation for Clostridium difficile-associated diarrhoea: a systematic review of randomised controlled trials. Med J Aust. 2017;207:166–172.
   PubMed Web of Science ®Google Scholar
• Maida M, Mcilroy J, Ianiro G, et al. Faecal microbiota transplantation as emerging treatment in European countries. Adv Exp Med Biol. 2018;1050:177–195.
   PubMed Web of Science ®Google Scholar
• Fuentes S, de Vos WM. How to manipulate the microbiota: fecal microbiota transplantation. Adv Exp Med Biol. 2016;902:143–153.
   PubMed Web of Science ®Google Scholar
• Weingarden AR, Vaughn BP. Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease. Gut Microbes. 2017;8:238–252.
   PubMed Web of Science ®Google Scholar
• Ianiro G, Masucci L, Quaranta G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection—single versus multiple infusions. Aliment Pharmacol Ther. 2018;48:152–159.
   PubMed Web of Science ®Google Scholar
• Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases. European society of clinical microbiology and infectious diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20:1–26.
   PubMed Web of Science ®Google Scholar
• Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66:569–580.
   PubMed Web of Science ®Google Scholar
• Terveer EM, van Beurden YH, Goorhuis A, et al. Working Group of The Netherlands Donor Feces Bank. Faecal microbiota transplantation in clinical practice. Gut. 2018;67:196.
   PubMedGoogle Scholar
• Kao D, Roach B, Silva M, et al. Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2017;318:1985–1993.
   PubMed Web of Science ®Google Scholar
• Jiang ZD, Ajami NJ, Petrosino JF, et al. Randomised clinical trial: faecal microbiota transplantation for recurrent Clostridum difficile infection - fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy. Aliment Pharmacol Ther. 2017;45:899–908.
   PubMed Web of Science ®Google Scholar
• Lee CH, Steiner T, Petrof EO, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2016;315(2):142–149.
   PubMed Web of Science ®Google Scholar
• Kassam Z, Lee CH, Yuan Y, et al. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108:500–508.
   PubMed Web of Science ®Google Scholar
• Fischer M, Sipe BW, Rogers NA, et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment Pharmacol Ther. 2015;42:470–476.
   PubMed Web of Science ®Google Scholar
• Fischer M, Sipe B, Cheng Y-W, et al. Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: a promising treatment approach. Gut Microbes. 2017;8:289–302.
   PubMed Web of Science ®Google Scholar
• Ianiro G, Valerio L, Masucci L, et al. Predictors of failure after single faecal microbiota transplantation in patients with recurrent Clostridium difficile infection: results from a 3- year, single-centre cohort study. Clin Microbiol Infect. 2017;23:337.e1–337.e3.
   Web of Science ®Google Scholar
• Fischer M, Kao D, Mehta SR, et al. Predictors of early failure after fecal microbiota transplantation for the therapy of Clostridium difficile infection: a multicenter study. Am J Gastroenterol. 2016;111:1024–1031.
   PubMed Web of Science ®Google Scholar
• Aroniadis OC, Brandt LJ, Greenberg A, et al. Long-term follow-up study of fecal microbiota transplantation for severe and/or complicated Clostridium difficile infection: a multicenter experience. J Clin Gastroenterol. 2016;50:398–402.
   PubMed Web of Science ®Google Scholar
• Allegretti JR, Kassam Z, Osman M, et al. The 5D framework: a clinical primer for fecal microbiota transplantation to treat Clostridium difficile infection. Gastrointest Endosc. 2018;87:18–29.
   PubMed Web of Science ®Google Scholar
• Dallas KB, Condren A, Divino C. Life after colectomy for fulminant Clostridium difficile colitis: a 7-year follow up study. Am J Surg. 2014;207:533–539.
   PubMed Web of Science ®Google Scholar
• Juul FE, Garborg K, Bretthauer MN, et al. Fecal microbiota transplantation for primary Clostridium difficile infection. N Engl J Med. 2018;378:2535–2536.
   PubMed Web of Science ®Google Scholar
• Orenstein R, Dubberke E, Hardi R, et al.; PUNCH CD Investigators. Safety and durability of RBX2660 (microbiota suspension) for recurrent Clostridium difficile infection: results of the PUNCH CD study. Clin Infect Dis. 2016;62:596–602.
   PubMed Web of Science ®Google Scholar
• Dubberke ER, Lee CH, Orenstein R, et al. Results from a randomized placebo-controlled clinical trial of a RBX2660-a microbiota-based drug for the prevention of recurrent Clostridium difficile infection. Clin Infect Dis. 2018;67(8):1198–1204.
   Google Scholar
• Seres Therapeutics Inc. Seres Therapeutics announces interim results from SER-109 phase 2 ECOSPOR Study in multiply recurrent Clostridium difficile infection; 2016. Available from: https://www.businesswire.com/news/home/20160729005385/en/Seres-Therapeutics-Announces-Interim-Results-SER-109-Phase
   Google Scholar
• ClinicalTrials.gov. Identifier: NCT03110133. Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects with Recurrent C. Diff (PRISM3). Available from: https://clinicaltrials.gov/ct2/show/NCT03110133
   Google Scholar
• Petrof EO, Gloor GB, Vanner SJ, et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: ‘RePOOPulating’ the gut. Microbiome. 2013;1:3.
   PubMed Web of Science ®Google Scholar
• Hoffmann DE, Palumbo FB, Ravel J, et al. A proposed definition of microbiota transplantation for regulatory purposes. Gut Microbes. 2017;8(3):208–213.
   PubMed Web of Science ®Google Scholar
• The National Institute for Health and Care Excellence (NICE). Faecal microbiota transplant for recurrent Clostridium difficile infection. Interventional procedures guidance. Available from: https://www.nice.org.uk/guidance/ipg485.
   Google Scholar
• Directive 2004/23/EC of the European Parliament and of the Council of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells. Off J Eur Union. 2004;L 102:48.
   Google Scholar
• Commission of the European Communities. Competent authorities for tissues and cells. Meeting of the competent authorities for tissues and cells 7–8 June 2012 summary report. Health and consumers directorate-general. Available from: http://ec.europa.eu/health/sites/health/files/blood_tissues_organs/docs/tissues_mi_20120607_en.pdf
   Google Scholar
• Commission of the European Communities.Competent authorities for tissues and cells. Meeting of the competent authorities for tissues and cells 2–3 June 2014 summary report. Health and consumers directorate-general. Available from: http://ec.europa.eu/health/sites/health/files/blood_tissues_organs/docs/ev_20140602_mi_en.pdf
   Google Scholar
• European Commission. Competent authorities on substances of human origin expert group (CASoHO E01718) meeting of the competent authorities for tissues and cells 3–4 December 2014 summary report 2014. Directorate-general for health and food safety. Available from: http://ec.europa.eu/health/blood_tissues_organs/docs/ev_20141203_sr_en.pdf
   Google Scholar
• Advies van de Hoge Gezondheidsraad HGR 9202 (Belgium). Recommendations on the safety and quality of fecal transplantation in humans. The recommended indication for fecal transplantation is recurrent or refractory Clostridium difficile infection. 2015. Available from: http://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/19103545/Aanbevelingen%20betreffende%20de%20therapeutische%20indicaties,%20de%20procedures,%20de%20veiligheid%20en%20de%20kwaliteit%20van%20de%20transplantatie%20van%20fecaal%20materiaal%20%28maart.pdf
   Google Scholar
• Megerlin F, Fouassier E. Le transfert de microbiote intestinal à finalité thérapeutique: quel droit applicable en France? Ann Pharm Françaises. 2014;72:363–374.
   PubMedGoogle Scholar
• Kump PK, Krause R, Allerberger F, et al. Faecal microbiota transplantation – the Austrian approach. Clin Microbiol Infect. 2014;20:1106–1111.
   PubMed Web of Science ®Google Scholar
• Petrof EO, Khoruts A. From stool transplants to next-generation microbiota therapeutics. Gastroenterology. 2014;146:1573–1582.
   PubMed Web of Science ®Google Scholar
• Ianiro G, Bibbò S, Gasbarrini A, et al. Therapeutic modulation of gut microbiota: current clinical applications and future perspectives. Curr Drug Targets. 2014;15(8):762–770.
   PubMed Web of Science ®Google Scholar
• Ianiro G, Bibbò S, Scaldaferri F, et al. Fecal microbiota transplantation in inflammatory bowel disease: beyond the excitement. Medicine (Baltimore). 2014 Oct;93(19):e97.
   PubMed Web of Science ®Google Scholar